Azenosertib
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Azenosertib
- Molecular weight
- 526.65
- Structure (SMILES)
- C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1ccc2c(n1)[C@@](O)(CC)CC2
- azenosertib
- Azenosertib
- Azenosertib [INN]
- Azenosertib [WHO-DD]
- azenosertib inn
- azenosertib who dd
- zn c3
- Zn-c3
- ZN-c3
- ZN-C3
- CAS registry numbers
- 2376146-48-2
- ChEMBL ID
- CHEMBL5095036
- InChIKey
- OXTSYWDBUVRXFF-GDLZYMKVSA-N
- PubChem compound IDs
- 139467635
- FDA ingredient codes (UNII)
- 9J13XU96Z1
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- azenosertib
- Type
- Synthetic organic
- Drug name stem
- -sertib
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- WEE1 G2 checkpoint kinase
- Gene symbol
- WEE1
- Protein identifier
- P30291
- Median affinity
- 8.41
- Affinity units
- pIC50
- Mechanism
- Serine/threonine-protein kinase WEE1 inhibitor
- Action type
- Inhibitor
- Target
- Wee1-like protein kinase
- Protein identifier
- P30291
Open Targets mechanisms
- Mechanism
- Serine/threonine-protein kinase WEE1 inhibitor
- Action type
- Inhibitor
- Target
- Wee1-like protein kinase
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Osteosarcoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000637
- Subject identifier
- D012516
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0002618
- Subject identifier
- D010190
- Condition
- Leukemia, Myeloid
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004643
- Subject identifier
- D007951
- Condition
- Carcinoma, Pancreatic Ductal
- Highest recorded phase
- 0.5
- Condition identifier
- MONDO:0005184
- Subject identifier
- D021441
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 1
- Condition identifier
- EFO_1000238
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002087
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002158
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004643
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005070
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005140
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005184
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005494
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0006047
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006196
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0008170
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0009807
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0015686
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0018874
- Highest recorded phase
- 1
- NCT04005690
- NCT04158336
- NCT04972422
- NCT04833582
- NCT05682170
- Hydrogen bond acceptors
- 10
- Hydrogen bond donors
- 2
- Polar surface area
- 104.34
- Calculated partition coefficient (ALogP)
- 3.2
- Calculated partition coefficient (XLogP)
- 3.7
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 7
- Heavy atoms
- 39
- Molecular formula
- C29H34N8O2
- Monoisotopic mass
- 526.28047236
- Natural product
- No
- Recorded assays
- 136
- Active assays
- 80
Active assay types
- Confirmatory
Related records
Trials (16)
- A Phase 1b Study of ZN-c3 in Chinese Subjects
- A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
- A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma
- A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors
- A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
- A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma
- A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Azenosertib in Uterine Serous Carcinoma: Biomarker Study
- Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
- Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)
- Targeted Pathway Inhibition in Patients With Pancreatic Cancer
- Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
- ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC
- ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer
- ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
In development for (6)
- Endometrial serous adenocarcinoma Phase 2
- Exocrine pancreatic carcinoma Early phase 1
- Myeloid leukemia Phase 1
- Neoplasm Phase 2
- Osteosarcoma Phase 1
- Pancreatic ductal adenocarcinoma Early phase 1
Targets (1)
- WEE1 Serine/threonine-protein kinase WEE1 inhibitor